A Phase III Study Comparing Etoposide and Cisplatin (EP) with Irinotecan and Cisplatin (IP) following EP plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for the Treatment of Limited-Stage Small-Cell Lung Cancer (EP/TRT-IPIII): JCOG0202-MF

A Phase III Study Comparing Etoposide and Cisplatin (EP) with Irinotecan and Cisplatin (IP) following EP plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for the Treatment of Limited-Stage Small-Cell Lung Cancer (EP/TRT-IPIII): JCOG0202-MF - A phase III study comparing IP with EP following EP/TRT for LD-SCLC JCOG0202-MF

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000095

Enrollment

270

Registered

2005-08-30

Start date

2002-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Limited-Stage Small-Cell Lung Cancer

Interventions

A: 3 courses of etoposide and cisplatin after induction chemoradiotherapy B: 3 courses of irinotecan and cisplatin after induction chemoradiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) cytologically, histologically proven small-cell lung cancer 2) limited disease 3) age 20-70 years old 4) performance status of 0-1 5) measurable disease 6) no prior treatment for small-cell lung cancer 7) no history of chemotherapy 8) adequate organ functions 9) written informed consent

Exclusion criteria

Exclusion criteria: 1) pericardial effusion 2) active concomitant malignancy 3) pregnant or lactating women 4) interstitial pneumonia/active lung fibrosis on chest x-ray, watery diarrhea, intestinal obstruction or paralysis, uncontrolled heart disease or a history of myocardial infarction within the previous 6 months, uncontrolled diabetes mellitus, active infection, psychological disease deemed unacceptable for inclusion to the study, long-term steroid treatment.

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
adverse events of induction chemoradiotherapy, chemotherapy after chemoradiotherapy, late radiation morbidity, serious adverse event, progression-free survival	—

Countries

Japan

Contacts

Public ContactKaoru Kubota, MD

JCOG0202 Coordinating Office Thoracic Oncology Division, National Cancer Center Hospital

JCOG_sir@ml.jcog.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026